Treatment of hyperpigmentation disorders

Pathak MA, Fitzpatrick TB, Nghiem P, Aghassi DS, eds. Sun-protective agents: formulations, effects, and side effects. In: Fitzpatrick Dermatology in General Medicine, New York: McGraw-Hill; 1993. p. 2742-60.

Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol 2001; 2: 213-7.

Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131: 1453-7.

Alena F, Dixon W, Thomas P, Jimbow K. Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-scysteaminylphenol in black and yellow hair follicles. J Invest Dermatol 1995; 104: 792-7.

Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis 1998; 39: 86-7.

Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis 1995; 32: 9-13.

Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther 1996; 276: 765-9.

Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328: 1438-43.

Kimbrough-Grccn CK, Griffiths CE, Finkel LJ, ct al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol 1994; 130: 727-33.

Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehiclecontrolled, clinical trial. Br J Dermatol 1993; 129: 415-21.

Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; lll: 40-8.

Galderma laboratories. Data on file.

Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol 2002; 29: 539-40.